ticlopidine and Atrioventricular Nodal Re-Entrant Tachycardia studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Research Excerpts

Excerpt	Relevance	Reference
"In the CLARITY-TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis In Myocardial Infarction 28) study, 3,491 patients underwent angiography a median of 3."	5.13	Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. ( Buros, JL; Cannon, CP; Gibson, CM; Josephson, ME; Lord, E; Murphy, SA; Pinto, DS; Pride, YB; Sabatine, MS; Shui, A; Zimetbaum, PJ, 2008)
"Nonsustained ventricular tachycardia (NSVT) is common after acute coronary syndrome (ACS) and a marker of increased risk of arrhythmogenic death."	2.82	Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bui, AH; Cannon, CP; Guo, J; Held, C; Himmelmann, A; Husted, S; Im, K; James, SK; Michelson, EL; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L, 2016)
"The incidence of ventricular tachycardia (VT) in the abciximab group was significantly lower than in the control group (p < 0."	1.30	The effects of antiplatelet agents in the prevention of ventricular tachyarrhythmias during acute myocardial ischemia in rats. ( Ahn, YK; Cho, JG; Cho, JH; Jeong, MH; Kang, JC; Kim, JW; Kim, NH; Kim, SH; Park, JC; Park, JH; Park, WS, 1999)

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Participants With Any Event From the Composite of All-cause Mortality, MI, and Stroke

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Bui, AH	1
Cannon, CP	3
Steg, PG	1
Storey, RF	1
Husted, S	1
Guo, J	1
Im, K	1
James, SK	1
Michelson, EL	1
Himmelmann, A	1
Held, C	1
Varenhorst, C	1
Wallentin, L	1
Scirica, BM	1
Pride, YB	2
Appelbaum, E	1
Lord, EE	1
Sloan, S	1
Sabatine, MS	2
Gibson, CM	2
Buros, JL	1
Lord, E	1
Shui, A	1
Murphy, SA	1
Pinto, DS	1
Zimetbaum, PJ	1
Josephson, ME	1
Ahn, YK	1
Cho, JG	1
Park, WS	1
Kim, NH	1
Kim, JW	1
Kim, SH	1
Cho, JH	1
Park, JH	1
Jeong, MH	1
Park, JC	1
Kang, JC	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872]	Phase 3	18,624 participants (Actual)	Interventional	2006-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI (Including Silent), Stroke, Recurrent Ischemia, Transient Ischemic Attack (TIA) and Other Arterial Thrombotic Events.

Intervention	Participants (Number)
TICAGRELOR	901
CLOPIDOGREL	1065

Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization

Intervention	Participants (Number)
TICAGRELOR	1290
CLOPIDOGREL	1456

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke

Intervention	Participants (Number)
TICAGRELOR	569
CLOPIDOGREL	668

Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Any Major Bleeding Event

Intervention	Participants (Number)
TICAGRELOR	864
CLOPIDOGREL	1014

Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	961
CLOPIDOGREL	929

Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding

Intervention	Participants (Number)
TICAGRELOR	619
CLOPIDOGREL	654

Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Death From Any Cause

Intervention	Participants (Number)
TICAGRELOR	329
CLOPIDOGREL	341

Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Death From Vascular Causes

Intervention	Participants (Number)
TICAGRELOR	399
CLOPIDOGREL	506

Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Major or Minor Bleeding

Intervention	Participants (Number)
TICAGRELOR	353
CLOPIDOGREL	442

Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With MI Event

Intervention	Participants (Number)
TICAGRELOR	1339
CLOPIDOGREL	1215

Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Non-CABG (Coronary Artery Bypass Graft) Related Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	504
CLOPIDOGREL	593

Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Non-procedural Major Bleeding

Intervention	Participants (Number)
TICAGRELOR	362
CLOPIDOGREL	306

Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months

Participants With Stroke

Intervention	Participants (Number)
TICAGRELOR	235
CLOPIDOGREL	180

Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24 Hour ECG Recorders for 1 Week at 1 Month Following Randomization

Intervention	Participants (Number)
TICAGRELOR	125
CLOPIDOGREL	106

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Participants With Ventricular Pauses of Greater Than or Equal to 3 Seconds in Patients Monitored by Holter 24-hour ECG Recorders for 1 Week Following Randomization

Intervention	Participants (Number)
TICAGRELOR	21
CLOPIDOGREL	16

Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization

Trials

3 trials available for ticlopidine and Atrioventricular Nodal Re-Entrant Tachycardia

Other Studies

1 other study available for ticlopidine and Atrioventricular Nodal Re-Entrant Tachycardia

Article	Year
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. Arrhythmia and electrophysiology, 2016, Volume: 9, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Cause of Death; Clopidogrel; Death, Sudden, Ca	2016
Relation between myocardial infarct size and ventricular tachyarrhythmia among patients with preserved left ventricular ejection fraction following fibrinolytic therapy for ST-segment elevation myocardial infarction. The American journal of cardiology, 2009, Aug-15, Volume: 104, Issue:4 Topics: Aged; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Incidence; Male; Middle Aged; Myocardia	2009
Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction. Journal of the American College of Cardiology, 2008, Feb-05, Volume: 51, Issue:5 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Circulati	2008